| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3329221 | Critical Reviews in Oncology/Hematology | 2011 | 10 Pages |
Abstract
The present state of the art for management of patients with febrile neutropenia has been reviewed as well as potential ways to improve it in the future. A major advance has been the possibility to predict, accurately and early, the risk of complications and death in those patients. While the algorithm for therapy in low-risk patients is presently straightforward, significant progresses are needed for patients who are at higher risk of presenting severe complications.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Jean Klastersky, Ahmad Awada, Mariane Paesmans, Mickael Aoun,
